Get the Stockscreener App
123.84
1.05%
-1.32
Pre-market:
124.08
0.24
+0.19%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $123.84, with a volume of 7.25M.
It is down -1.05% in the last 24 hours and down -7.83% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$125.16
Open:
$125.27
24h Volume:
7.25M
Relative Volume:
1.09
Market Cap:
$153.76B
Revenue:
$29.79B
Net Income/Loss:
$9.22B
P/E Ratio:
16.85
EPS:
7.3494
Net Cash Flow:
$10.23B
1W Performance:
+0.06%
1M Performance:
-7.83%
6M Performance:
-1.46%
1Y Performance:
+16.91%
1-Day Range:
$123.67
$126.95
1-Week Range:
$123.00
$127.27
52-Week Range:
$105.79
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
123.84 | 155.39B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,127.69 | 996.31B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
244.88 | 580.14B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
243.14 | 415.00B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
125.45 | 297.86B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.12 | 292.17B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Jefferies | Buy |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-11-26 | Reiterated | Needham | Buy |
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know - Yahoo Finance UK
Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer - Benzinga
Gilead Sciences updates oncology pipeline, shares steady on NASDAQ - Ad-hoc-news.de
Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use - Yahoo Finance Singapore
Gilead’s TROP-2 Trodelvy, Keytruda combo win first-line FDA nods for breast cancer - BioSpace
New FDA Nod Keeps Gilead Drug Competitive With AstraZeneca & Daiichi in Breast Cancer - MedCity News
Gilead Says FDA Approves Trodelvy for First-Line Treatment of Advanced Triple-Negative Breast Cancer - marketscreener.com
GILD Receives FDA Approval for Trodelvy in Triple-Negative Breas - GuruFocus
FDA approves Gilead’s Trodelvy for first-line breast cancer By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Galectin Therapeutics (GALT) and Gilead Sciences (GILD) - The Globe and Mail
Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC - Yahoo Finance Singapore
Astellas Padcev and Gilead's Trodelvy grab key EU approvals - pharmaphorum
5 Set-It-and-Forget-It Stocks to Buy Right Now - Insider Monkey
Gilead Sciences, Inc. Shs Cert Deposito Arg Repr 1/4 Sh Trade Ideas — BCBA:GILD.CI - TradingView
Gilead Sciences highlights ongoing commitment to Pride, inclusion in community and workplace - ABC7 Bay Area
Gilead receives EU nod for Trodelvy in first-line metastatic triple-negative breast cancer - grafa.com
GILD Gains EU Approval for Trodelvy in Treating Triple-Negative Breast Cancer - GuruFocus
Gilead Sciences: The Market Is Underestimating Its Growth Runway (NASDAQ:GILD) - Seeking Alpha
Gilead’s Trodelvy wins EU approval for first-line breast cancer - Investing.com
Gilead Sciences Receives EU Marketing Approval for Trodelvy as Breast Cancer Treatment - marketscreener.com
Gilead Sciences draws Cantor support, shares sit below $155 target - AD HOC NEWS
Jared Moskowitz from Florida’s 23rd District Trades in Cencora and Gilead Sciences Stocks - Investing.com Canada
Cantor Fitzgerald reiterates Gilead Sciences stock Overweight rating at $155 - Investing.com UK
Gilead Sciences wins FDA backing for weekly HIV pill, Cantor sticks to Overweight call on the shares - AD HOC NEWS
Gilead Sciences Stock (GILD) Opinions on Recent Congressional Insider Activity - Quiver Quantitative
Could This FDA Milestone Unlock Gilead’s (GILD) Next Big Growth Driver? - Insider Monkey
Cantor Fitzgerald reiterates Gilead Sciences stock Overweight rating at $155 By Investing.com - Investing.com Canada
How Investors May Respond To Gilead Sciences (GILD) FDA Review Of Once‑Weekly Oral HIV PrEP - Sahm
Gilead Sciences (GILD) Gets a Buy from Scotiabank - The Globe and Mail
Gilead Sciences stock price forecast: $120.19 support in focus as GILD slides 1.82% - Traders Union
GILD News | GILEAD SCIENCES INC (NASDAQ:GILD) - ChartMill
Gilead’s Work to Help End the HIV Epidemic, One Year after Launch of its Twice-Yearly Prevention Medication - Gilead Sciences
Vascular Dementia Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | Pfizer, Gilead Sciences, ViiV Healthcare - Barchart.com
Gilead Sciences Inc. stock outperforms competitors despite losses on the day - MarketWatch
Gilead Sciences Cell Therapy Move Draws Biotech Attention - Kalkine Media
Gilead Sciences StockFDA accepts filing for weekly HIV prevention pill - AD HOC NEWS
World Economic Forum, Takeda and Gilead executives confirmed for Women's HealthX in Boston - FemTech World
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know - Yahoo Finance
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Why Gilead Sciences bets on Sunlenca as a long-acting HIV anchor - AD HOC NEWS
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Pharma Giants Navigate A Busy Deal-Making Backdrop - Kalkine Media
Gilead Sciences (GILD) Donates Remdesivir to Uganda - Insider Monkey
Gilead Sciences Inc (GILD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Voya Global High Dividend Low Volatility Portfolio's Gilead Sciences Inc(GILD) Holding History - GuruFocus
Gilead Sciences (GILD) Receives a Buy from Citi - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Irhythm Technologies (IRTC), Gilead Sciences (GILD) - The Globe and Mail
The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK - The Globe and Mail
Gilead Sciences chief comm officer sells $371k in stock - Investing.com UK
[Press release] FDA accepts Gilead’s application for investigational once-weekly oral Yeztugo, potentially the first long-acting pill for HIV prevention - European AIDS Treatment Group
Gilead Sciences chief comm officer sells $371k in stock By Investing.com - Investing.com Nigeria
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gilead Sciences Inc Stock (GILD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | Chief Financial Officer |
Jun 15 '26 |
Sale |
125.40 |
3,000 |
376,200 |
171,646 |
1.54%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):